Anna Berry, MD
Dr Berry is the director of Molecular Pathology at CellNetix. Prior to joining CellNetix, she was Associate Professor of Pathology at University of California San Francisco. She is board...
Designed by pathologists and oncologists to create a better platform to diagnose and treat your patients.
Molecular pathology is the study of molecules in a disease state. At CellNetix we utilize sensitive molecular tools that often confirm ambiguous diagnoses suspected by microscopic evaluation, guide therapeutic decisions and assess treatments. Molecular techniques can also assist with predicting the effectiveness of some important medications as well as identifying specific targets in individual patients’ tumors for new therapeutic modalities “personalized medicine”.
NGS is similar in concept to traditional Sanger sequencing, where the bases of a given DNA fragment are sequentially identified through DNA re-synthesis. NGS extends this process in a massively parallel fashion across millions of reactions, rather than a limited number of DNA fragments. This significantly increases the coverage for variant calls, dramatically reduces the cost per gene per sample, and enables high throughput workflow for simultaneous screening of different types of mutations in many genes from multiple samples.
With the NEW Symgene79™ targeted gene panel, you can offer clients competitively priced, cutting-edge testing that isolates the 79 most actionable genes, for more relevant results, affordably delivered in weeks–not months. Learn more about Symgene here.
Using the Illumina Miseq platform, an individual genomic DNA (gDNA) sample is first prepared into a library of small segments with adaptors and indexes attached. Indexed samples from multiple individuals are then pooled and loaded onto a single sequencing cartridge. Each fragment of the pooled samples is attached to the solid surface through the adaptor, and then uniformly and accurately sequenced in millions of parallel reactions. All variants are interpreted by our pathologists for clinical reference using publicly available databases and medical literature, and then used to create a concise and comprehensible report that can inform timely and appropriate clinical care for cancer patients.
|LCK||LYN||MAP2K1 (MEK1)||MAP2K2 (MEK2)||MDM2||MET||MLH1|
If you are not setup with an electronic interface for NGS testing, please contact your local representative or use the below requisition form and fax it to 206-215-5935 or 866-721-9697.Requisition Form